Search - tctmd.com

Displaying 101 - 120 of 204

Sort: Relevancy | Date

Presentation TCT 2016

ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal Arteries

Presenter: Martin B. Leon, Louis A. Cannon, Sean P. Lyden

November 02, 2016

Presentation TCT 2016

Local Ultrasound to Enhance Paclitaxel Delivery after Femoro-Popliteal Treatment in Critical Limb Ischemia: Immediate and Midterm Results of the PACUS Trial

Presenter: Michael D. Dake, Kenneth Rosenfield, Costantino Del Giudice

November 01, 2016

Presentation TCT 2016

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

Presenter: William A. Gray, Stephan Windecker, John R. Laird Jr.

October 31, 2016

Presentation TCT 2016

Multicenter Global Registry Report of the Two-year Outcomes with a Paclitaxel-Coated Balloon in Patients with Complex Femoropopliteal Lesions

Presenter: Thomas F. Luscher, Patrick W. Serruys, D. Christopher Metzger

October 31, 2016

Presentation TCT 2016

TCT 74: A Serial Three-Year and Nine-Year Optical Coherence Tomography Assessment of Vascular Healing Response to Sirolimus and Paclitaxel-Eluting Stents

Presenter: Hector M. Garcia-Garcia, Ik-Kyung Jang, Mariusz Tomaniak

October 31, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

Presentation TCT 2015

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Presenter: Cindy L. Grines, Upendra Kaul

October 14, 2015

Presentation TCT 2015

Early First-in-Human Data of Paclitaxel Drug-Coated Chocolate PTCA Coronary Balloon Catheters in De Novo Coronary Lesions

Presenter: Andrea Abizaid, Daniel Burkhoff, J. A. Mustapha

October 14, 2015

Presentation TCT 2015

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Presenter: Upendra Kaul

October 14, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Conference News TCT 2015

ISAR-DESIRE 4: Scoring Balloon Predilation Effective at 1 Year in Patients With DES Restenosis

October 14, 2015

News Conference News TCT 2015

IN.PACT SFA: Benefits of DCB Persist at 2 Years

October 14, 2015

News Conference News TCT 2015

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

October 12, 2015

News Conference News TCT 2015

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

October 12, 2015

News Conference News TCT 2015

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

October 12, 2015

Presentation TCT 2014

Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings

Presenter: Todd J. Brinton, Ian T. Meredith, Greg L. Kaluza, Freek Nijhoff

September 16, 2014

Presentation TCT 2014

Detection of Paclitaxel Contamination Resulting from the Simulated Clinical Use of Drug Coated Balloon Catheters

Presenter: Charisse Ward

September 16, 2014

Presentation TCT 2014

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

Presenter: Georgios Vlachojannis

September 16, 2014

Presentation TCT 2014

New Ultrasound Enhanced Paclitaxel Therapy to Treat Critical Limb Ischemia

Presenter: Chaim S. Lotan, Julio C. Palmaz, Mark A. Turco, Roberto Gandini

September 15, 2014

News Conference News TCT 2014

Less Mortality with Paclitaxel-Coated Balloon vs. Stent in DES Restenosis

September 15, 2014

Advertisement

ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal Arteries

Local Ultrasound to Enhance Paclitaxel Delivery after Femoro-Popliteal Treatment in Critical Limb Ischemia: Immediate and Midterm Results of the PACUS Trial

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

Multicenter Global Registry Report of the Two-year Outcomes with a Paclitaxel-Coated Balloon in Patients with Complex Femoropopliteal Lesions

TCT 74: A Serial Three-Year and Nine-Year Optical Coherence Tomography Assessment of Vascular Healing Response to Sirolimus and Paclitaxel-Eluting Stents

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Early First-in-Human Data of Paclitaxel Drug-Coated Chocolate PTCA Coronary Balloon Catheters in De Novo Coronary Lesions

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

ISAR-DESIRE 4: Scoring Balloon Predilation Effective at 1 Year in Patients With DES Restenosis

IN.PACT SFA: Benefits of DCB Persist at 2 Years

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings

Detection of Paclitaxel Contamination Resulting from the Simulated Clinical Use of Drug Coated Balloon Catheters

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

New Ultrasound Enhanced Paclitaxel Therapy to Treat Critical Limb Ischemia

Less Mortality with Paclitaxel-Coated Balloon vs. Stent in DES Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content